Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2021-01-12 Regulatory Filings
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'PRESS RELEASE - REGULATED INFORMATION' and announces a specific corporate event: 'Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study'. It provides key operational updates (recruitment timelines, results anticipation) and context about the drug/trial. This format—a brief, timely announcement of a significant operational milestone, often released under regulatory requirements—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on operational/clinical progress rather than just dividends (DIV) or management changes (MANG), it fits best as an Earnings Release (ER) if it were quarterly results, or a general Regulatory Filing (RNS). Given the context of clinical trial updates, which are often released via press release, and the 'REGULATED INFORMATION' header, RNS is a strong candidate. However, ERs often include operational updates alongside financial highlights. Since this is a clinical trial update rather than a summary of financial performance metrics (revenue, EPS), and it is a 'PRESS RELEASE', it is most accurately classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company uses ERs for major operational milestones. Given the lack of explicit financial figures (like revenue or profit), RNS is the safer, broader classification for a regulated press release detailing operational progress, though ER is also plausible if this is the primary vehicle for such news. I will lean towards RNS as the most appropriate fallback for a regulated press release that isn't a specific financial report or management change.
2021-01-12 English
Bone Therapeutics traite le premier patient de l’étude de Phase IIb évaluant ALLOB dans les fractures du tibia
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled 'PRESS RELEASE COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE' and dated January 12, 2020. It announces a specific operational milestone: 'Bone Therapeutics traite le premier patient de l'étude de Phase IIb évaluant ALLOB dans les fractures du tibia' (Bone Therapeutics treats the first patient in the Phase IIb study evaluating ALLOB in tibia fractures). This type of announcement, detailing clinical trial progress, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally as a Regulatory Filing (RNS) if it's a broad operational update that doesn't fit other specific categories like ER, CT, or IR. Since this is a press release announcing a clinical trial start and providing future timelines (recruitment end H1 2022, results H2 2022), it functions as a material, non-financial operational update. Given the options, it is a general regulatory announcement that doesn't fit the specific financial report types (10-K, IR, ER) or specific corporate actions (CAP, DIV, DIRS). Therefore, the most appropriate general category for a material regulatory press release that isn't a formal financial report or earnings summary is Regulatory Filings (RNS).
2021-01-12 French
3EN.Bone Therapeutics_EGM 8 February 2021_Information on shareholders_ rights.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document explicitly discusses the rights of shareholders regarding an upcoming Extraordinary General Meeting (EGM) scheduled for February 8, 2021. It details procedures for shareholders to include items on the agenda, submit proposals, and ask written questions, referencing specific articles of the Belgian Company Code (Articles 7:130 and 7:139). This type of detailed procedural information concerning shareholder rights and meeting logistics is characteristic of materials distributed prior to a general meeting to solicit participation and votes, which aligns best with the Proxy Solicitation & Information Statement (PSI) definition, or potentially AGM-R if the EGM is treated similarly to an AGM for classification purposes. However, since it focuses heavily on the mechanics of shareholder participation rights (agenda setting, voting instructions, asking questions) rather than the final results or the meeting presentation itself, PSI is the most precise fit among the options, as it covers pre-meeting information sent to solicit votes/participation. Given the context of an EGM and the focus on shareholder rights/proposals, PSI is the strongest match.
2021-01-08 English
3FR.Bone Therapeutics_AGE 8 février 2021_information_sur_les_droits_des_actionnaires.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document explicitly discusses shareholder rights regarding an upcoming Extraordinary General Meeting (Assemblée Générale Extraordinaire) scheduled for February 8, 2021. It details procedures for shareholders to add items to the agenda (Article 7:130) and to submit written questions prior to the meeting (Article 7:139). This content is directly related to the procedures and information provided to shareholders in preparation for a general meeting, specifically concerning voting rights, agenda setting, and proxy forms. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. While it relates to an AGM, the focus is on the procedural rights leading up to it, making PSI more specific than AGM-R (which usually covers the presentation/materials *from* the meeting).
2021-01-08 French
2EN.20210208_BOTHE_Proxy form_EGM.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is explicitly titled 'PROXY FORM' and details the process for a shareholder to appoint a representative ('proxy holder') for an 'extraordinary general meeting' (EGM) scheduled for February 8, 2021. It outlines the agenda, proposed resolutions (capital reduction, power of attorney for formalities), voting procedures, and quorum requirements. This content is characteristic of materials used to solicit shareholder votes and provide necessary information ahead of a general meeting, which aligns directly with the definition of a Proxy Solicitation & Information Statement (PSI). It is not the final voting results (DVA), the full annual report (10-K), or a general announcement of a report (RPA).
2021-01-08 English
2FR.20210208_BOTHE_Procuration_AGE.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled "PROCURATION" and contains instructions and a form for an actionnaire (shareholder) to appoint a representative (mandataire) to vote at an "assemblée générale extraordinaire" (Extraordinary General Meeting - EGM) scheduled for February 8, 2021. It details the agenda, including resolutions for capital reduction and statutory changes, and outlines voting procedures and quorum requirements. This material is directly related to soliciting shareholder votes and providing necessary information for that purpose, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the final voting results (DVA), nor is it the full AGM presentation (AGM-R), but the document used to grant proxy authority prior to the meeting.
2021-01-08 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.